Shakil Husain, Essa Ahmad, Malhotra Armaan K, Kiss Alex, Witiw Christopher D, Redelmeier Donald A, Wilson Jefferson R
1Division of Neurosurgery, Department of Surgery, University of Toronto.
3Institute of Health Policy Management and Evaluation, University of Toronto, Ontario, Canada.
J Neurosurg Spine. 2024 Nov 29;42(2):215-229. doi: 10.3171/2024.7.SPINE24518. Print 2025 Feb 1.
This systematic review and meta-analysis compared minimally invasive surgery (MIS) to open surgery for treatment of spinal metastases with respect to perioperative outcomes. Few studies have systemically assessed the body of evidence on this topic.
A systematic review of EMBASE and PubMed from database inception to December 2023 was performed to identify studies comparing MIS with open surgery for the treatment of spine metastases. Nine outcomes were collected: estimated blood loss (EBL), operative time, hospital length of stay (LOS), risk of revision, risk of neurological deterioration, likelihood of receiving postoperative radiation therapy, time to radiation therapy, time to chemotherapy, and treatment of pain measured through patient-reported visual analog scale (VAS) scores. Meta regression was used to estimate adjusted mean differences (aMDs) and adjusted odds ratios (aORs) for outcomes. Certainty of evidence was appraised using the Grading of Recommendations, Assessment, Development and Evaluations approach.
There were 34 eligible studies including 1656 patients with spinal metastases; 904 (54.6%) patients were treated with MIS and 752 (45.4%) were treated with open surgery. MIS was associated with significantly less blood loss (aMD -602 mL, 95% CI -1204 to -0.2 mL; I2 = 97%) with a moderate certainty of evidence. MIS was found to be noninferior with respect to operative time (aMD -2.6 minutes, 95% CI -53.3 to 48.1 minutes; I2 = 88%), risk of revision (aOR 0.9, 95% CI 0.8-1.1; I2 < 0.01), risk of neurological deterioration (aOR 0.9, 95% CI 0.8-1.0; I2 < 0.01), likelihood of postoperative radiation therapy (aOR 0.9, 95% CI 0.7-1.4; I2 < 0.01), and postoperative VAS score (aMD -0.6, 95% CI -1.5 to 0.4; I2 = 52%) with low certainty of evidence. MIS was associated with significantly shorter time to chemotherapy (MD -0.9 weeks, 95% CI -1.9 to -0.01 weeks; I2 = 22%), with very low certainty of evidence. Inferences for LOS and time to radiation were indeterminate; however, we found a trend toward earlier radiation therapy with MIS that was significant in the subgroup of patients treated with decompression and fusion.
Treatment with MIS compared with open surgery was associated with reduced EBL, shorter time to chemotherapy, similar operative time, and similar reductions in postoperative pain. Limitations were largely due to heterogeneity across studies. Future research among subgroups is very likely to improve certainty in the comparative effect estimates.
本系统评价和荟萃分析比较了微创手术(MIS)与开放手术治疗脊柱转移瘤的围手术期结局。很少有研究对该主题的证据进行系统评估。
对EMBASE和PubMed从建库至2023年12月进行系统评价,以识别比较MIS与开放手术治疗脊柱转移瘤的研究。收集了9项结局指标:估计失血量(EBL)、手术时间、住院时间(LOS)、翻修风险、神经功能恶化风险、接受术后放疗的可能性、放疗时间、化疗时间以及通过患者报告的视觉模拟量表(VAS)评分衡量的疼痛治疗情况。采用Meta回归估计结局指标的调整均数差(aMDs)和调整比值比(aORs)。使用推荐分级、评估、制定和评价方法评估证据的确定性。
有34项符合条件的研究,包括1656例脊柱转移瘤患者;904例(54.6%)患者接受了MIS治疗,752例(45.4%)患者接受了开放手术治疗。MIS与显著更少的失血量相关(aMD -602 mL,95% CI -1204至-0.2 mL;I² = 97%),证据确定性为中等。发现MIS在手术时间方面非劣效(aMD -2.6分钟,95% CI -53.3至48.1分钟;I² = 88%)、翻修风险(aOR 0.9,95% CI 0.8 - 1.1;I² < 0.01)、神经功能恶化风险(aOR 0.9,95% CI 0.8 - 1.0;I² < 0.01)、术后放疗可能性(aOR 0.9,95% CI 0.7 - 1.4;I² < 0.01)以及术后VAS评分(aMD -0.6,95% CI -1.5至0.4;I² = 52%)方面,证据确定性较低。MIS与显著更短化疗时间相关(MD -0.9周,95% CI -1.9至-0.01周;I² = 22%),证据确定性非常低。关于LOS和放疗时间的推断不确定;然而,我们发现MIS有更早进行放疗的趋势,在接受减压和融合治疗的患者亚组中这一趋势显著。
与开放手术相比,MIS治疗与EBL减少、化疗时间缩短、手术时间相似以及术后疼痛减轻相似相关。局限性主要归因于各研究间的异质性。未来亚组研究很可能会提高比较效应估计的确定性。